{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:03:33Z","timestamp":1789502613343,"version":"build-2803163510"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"13","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01HL130336"],"award-info":[{"award-number":["R01HL130336"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0165"],"award-info":[{"award-number":["W81XWH-16-1-0165"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001771","name":"Tuberous Sclerosis Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001771","name":"Tuberous Sclerosis Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005963","name":"LAM Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008552","name":"Brigham Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008552","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Tuberous sclerosis complex (TSC) is an autosomal dominant disease characterized by multiorgan hamartomas, including renal angiomyolipomas and pulmonary lymphangioleiomyomatosis (LAM). TSC2 deficiency leads to hyperactivation of mTOR Complex 1 (mTORC1), a master regulator of cell growth and metabolism. Phospholipid metabolism is dysregulated upon TSC2 loss, causing enhanced production of lysophosphatidylcholine (LPC) species by TSC2-deficient tumor cells. LPC is the major substrate of the secreted lysophospholipase D autotaxin (ATX), which generates two bioactive lipids, lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P). We report here that ATX expression is upregulated in human renal angiomyolipoma-derived TSC2-deficient cells compared with TSC2 add-back cells. Inhibition of ATX via the clinically developed compound GLPG1690 suppressed TSC2-loss associated oncogenicity in vitro and in vivo and induced apoptosis in TSC2-deficient cells. GLPG1690 suppressed AKT and ERK1\/2 signaling and profoundly impacted the transcriptome of these cells while inducing minor gene expression changes in TSC2 add-back cells. RNA-sequencing studies revealed transcriptomic signatures of LPA and S1P, suggesting an LPA\/S1P-mediated reprogramming of the TSC lipidome. In addition, supplementation of LPA or S1P rescued proliferation and viability, neutral lipid content, and AKT or ERK1\/2 signaling in human TSC2-deficient cells treated with GLPG1690. Importantly, TSC-associated renal angiomyolipomas have higher expression of LPA receptor 1 and S1P receptor 3 compared with normal kidney. These studies increase our understanding of TSC2-deficient cell metabolism, leading to novel potential therapeutic opportunities for TSC and LAM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study identifies activation of the ATX\u2013LPA\/S1P pathway as a novel mode of metabolic dysregulation upon TSC2 loss, highlighting critical roles for ATX in TSC2-deficient cell fitness and in TSC tumorigenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-19-2884","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T14:45:28Z","timestamp":1589208328000},"page":"2751-2763","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic Targeting of the Secreted Lysophospholipase D Autotaxin Suppresses Tuberous Sclerosis Complex-Associated Tumorigenesis"],"prefix":"10.1158","volume":"80","author":[{"given":"You","family":"Feng","sequence":"first","affiliation":[{"name":"1Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Mischler","sequence":"additional","affiliation":[{"name":"1Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish C.","family":"Gurung","sequence":"additional","affiliation":[{"name":"1Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor R.","family":"Kavanagh","sequence":"additional","affiliation":[{"name":"1Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigoriy","family":"Androsov","sequence":"additional","affiliation":[{"name":"1Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1036-6367","authenticated-orcid":false,"given":"Peter M.","family":"Sadow","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"3Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary T.","family":"Herbert","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"4Molecular Biology Core Facilities, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Priolo","sequence":"additional","affiliation":[{"name":"1Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"2022061706353231500_bib1","doi-asserted-by":"crossref","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","article-title":"Tuberous sclerosis complex","volume":"2","author":"Henske","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2022061706353231500_bib2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ajmg.c.31638","article-title":"Pulmonary manifestations in tuberous sclerosis complex","volume":"178","author":"Gupta","year":"2018","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"2022061706353231500_bib3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molcel.2010.06.022","article-title":"Activation of a metabolic gene regulatory network downstream of mTOR complex 1","volume":"39","author":"Duvel","year":"2010","journal-title":"Mol Cell"},{"key":"2022061706353231500_bib4","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1242\/jcs.051011","article-title":"mTOR signaling at a glance","volume":"122","author":"Laplante","year":"2009","journal-title":"J Cell Sci"},{"key":"2022061706353231500_bib5","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"2022061706353231500_bib6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1165\/rcmb.2014-0379RC","article-title":"Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis","volume":"53","author":"Priolo","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2022061706353231500_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1541-7786.MCR-13-0258-T","article-title":"Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide","volume":"12","author":"Parkhitko","year":"2014","journal-title":"Mol Cancer Res"},{"key":"2022061706353231500_bib8","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1126\/science.1228792","article-title":"Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1","volume":"339","author":"Ben-Sahra","year":"2013","journal-title":"Science"},{"key":"2022061706353231500_bib9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N Engl J Med"},{"key":"2022061706353231500_bib10","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1590\/S1806-37132011000400002","article-title":"The way forward in lymphangioleiomyomatosis: a trial for every patient, every patient in a trial","volume":"37","author":"McCormack","year":"2011","journal-title":"J Bras Pneumol"},{"key":"2022061706353231500_bib11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.chest.2019.05.038","article-title":"Metabolic changes in patients with lymphangioleiomyomatosis treated with sirolimus and hydroxychloroquine","volume":"156","author":"Tang","year":"2019","journal-title":"Chest"},{"key":"2022061706353231500_bib12","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1073\/pnas.1001529107","article-title":"Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation","volume":"107","author":"Albers","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706353231500_bib13","first-page":"5446","article-title":"Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate","volume":"63","author":"Clair","year":"2003","journal-title":"Cancer Res"},{"key":"2022061706353231500_bib14","first-page":"733","article-title":"Identification of genes associated with metastasis of mammary carcinoma in metastatic versus non-metastatic cell lines","volume":"22","author":"Euer","year":"2002","journal-title":"Anticancer Res"},{"key":"2022061706353231500_bib15","doi-asserted-by":"crossref","first-page":"L694","DOI":"10.1152\/ajplung.00204.2003","article-title":"Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways","volume":"286","author":"Yu","year":"2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2022061706353231500_bib16","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","article-title":"Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis","volume":"97","author":"Carsillo","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706353231500_bib17","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1172\/JCI200317222","article-title":"Loss of Tsc1\/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR","volume":"112","author":"Zhang","year":"2003","journal-title":"J Clin Invest"},{"key":"2022061706353231500_bib18","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.1158\/0008-5472.CAN-14-1490","article-title":"AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer","volume":"74","author":"Priolo","year":"2014","journal-title":"Cancer Res"},{"key":"2022061706353231500_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2022061706353231500_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2022061706353231500_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nbt.1621","article-title":"Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation","volume":"28","author":"Trapnell","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2022061706353231500_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12859-018-2139-9","article-title":"VIPER: visualization pipeline for RNA-seq, a snakemake workflow for efficient and complete RNA-seq analysis","volume":"19","author":"Cornwell","year":"2018","journal-title":"BMC Bioinformatics"},{"key":"2022061706353231500_bib23","article-title":"GSEABase: Gene set enrichment data structures and methods","author":"Morgan","year":"2019"},{"key":"2022061706353231500_bib24","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706353231500_bib25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"key":"2022061706353231500_bib26","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"2022061706353231500_bib27","doi-asserted-by":"crossref","first-page":"15816","DOI":"10.1038\/ncomms15816","article-title":"The genomic landscape of tuberous sclerosis complex","volume":"8","author":"Martin","year":"2017","journal-title":"Nat Commun"},{"key":"2022061706353231500_bib28","first-page":"4245","article-title":"ATX-LPA axis facilitates estrogeninduced endometrial cancer cell proliferation via MAPK\/ERK signaling pathway","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Med Rep"},{"key":"2022061706353231500_bib29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10555-011-9319-7","article-title":"Autotaxin and LPA receptor signaling in cancer","volume":"30","author":"Houben","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"2022061706353231500_bib30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12031-014-0478-1","article-title":"Activation of S1P(1) receptor regulates PI3K\/Akt\/FoxO3a pathway in response to oxidative stress in PC12 cells","volume":"56","author":"Safarian","year":"2015","journal-title":"J Mol Neurosci"},{"key":"2022061706353231500_bib31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/path.4879","article-title":"Oncogenic S1P signalling in EBV-associated nasopharyngeal carcinoma activates AKT and promotes cell migration through S1P receptor 3","volume":"242","author":"Lee","year":"2017","journal-title":"J Pathol"},{"key":"2022061706353231500_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/1759091414558416","article-title":"Convergent regulation of neuronal differentiation and Erk and Akt kinases in human neural progenitor cells by lysophosphatidic acid, sphingosine 1-phosphate, and LIF: specific roles for the LPA1 receptor","volume":"6","author":"Callihan","year":"2014","journal-title":"ASN Neuro"},{"key":"2022061706353231500_bib33","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1038\/cddis.2013.455","article-title":"Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase\/protein kinase C-mediated upregulation of Mcl-1","volume":"4","author":"Rutherford","year":"2013","journal-title":"Cell Death Dis"},{"key":"2022061706353231500_bib34","doi-asserted-by":"crossref","first-page":"9498","DOI":"10.1074\/jbc.M410455200","article-title":"Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT\/PKB","volume":"280","author":"Hu","year":"2005","journal-title":"J Biol Chem"},{"key":"2022061706353231500_bib35","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0960-9822(07)00485-X","article-title":"A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation","volume":"8","author":"Robinson","year":"1998","journal-title":"Curr Biol"},{"key":"2022061706353231500_bib36","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cmet.2011.07.013","article-title":"Phosphatidylcholine synthesis for lipid droplet expansion is mediated by localized activation of CTP:phosphocholine cytidylyltransferase","volume":"14","author":"Krahmer","year":"2011","journal-title":"Cell Metab"},{"key":"2022061706353231500_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nsmb.1998","article-title":"Crystal structure of autotaxin and insight into GPCR activation by lipid mediators","volume":"18","author":"Nishimasu","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"2022061706353231500_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/cancers10030073","article-title":"Coming of age for autotaxin and lysophosphatidate signaling: clinical applications for preventing, detecting and targeting tumor-promoting inflammation","volume":"10","author":"Benesch","year":"2018","journal-title":"Cancers"},{"key":"2022061706353231500_bib39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.plipres.2015.02.001","article-title":"Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer","volume":"58","author":"Barbayianni","year":"2015","journal-title":"Prog Lipid Res"},{"key":"2022061706353231500_bib40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.12703\/P6-109","article-title":"S1P signaling: new therapies and opportunities","volume":"6","author":"Gonzalez-Cabrera","year":"2014","journal-title":"F1000Prime Rep"},{"key":"2022061706353231500_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0303-7207(01)00441-5","article-title":"Subtype-specific, differential activities of the EDG family receptors for sphingosine-1-phosphate, a novel lysophospholipid mediator","volume":"177","author":"Takuwa","year":"2001","journal-title":"Mol Cell Endocrinol"},{"key":"2022061706353231500_bib42","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.pharmthera.2007.04.006","article-title":"Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology","volume":"115","author":"Brinkmann","year":"2007","journal-title":"Pharmacol Ther"},{"key":"2022061706353231500_bib43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3727\/096504009790217399","article-title":"Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms","volume":"18","author":"Boucharaba","year":"2009","journal-title":"Oncol Res"},{"key":"2022061706353231500_bib44","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ijc.26476","article-title":"Lysophosphatidic acid receptor 2\/3-mediated IL-8-dependent angiogenesis in cervical cancer cells","volume":"131","author":"Chen","year":"2012","journal-title":"Int J Cancer"},{"key":"2022061706353231500_bib45","first-page":"1706","article-title":"Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1","volume":"63","author":"Shida","year":"2003","journal-title":"Cancer Res"},{"key":"2022061706353231500_bib46","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1194\/jlr.R046458","article-title":"LPA receptor signaling: pharmacology, physiology, and pathophysiology","volume":"55","author":"Yung","year":"2014","journal-title":"J Lipid Res"},{"key":"2022061706353231500_bib47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cellsig.2017.03.002","article-title":"Mechanisms of sphingosine 1-phosphate receptor signalling in cancer","volume":"34","author":"Patmanathan","year":"2017","journal-title":"Cell Signal"},{"key":"2022061706353231500_bib48","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/jcph.1424","article-title":"Safety, pharmacokinetics, and pharmacodynamics of the autotaxin inhibitor GLPG1690 in healthy subjects: phase 1 randomized trials","volume":"59","author":"van der Aar","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2022061706353231500_bib49","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial","volume":"6","author":"Maher","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2022061706353231500_bib50","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1194\/jlr.M057661","article-title":"Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate","volume":"56","author":"Benesch","year":"2015","journal-title":"J Lipid Res"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/13\/2751\/2794734\/2751.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/13\/2751\/2794734\/2751.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T16:01:51Z","timestamp":1655481711000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/80\/13\/2751\/645403\/Therapeutic-Targeting-of-the-Secreted"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":50,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2020,7,2]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-19-2884","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22425405.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425387.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425390","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425402.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425408.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6512022","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425393.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425390.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425399.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425396.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425405","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425408","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425402","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425396","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425393","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425399","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6512022.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22425387","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}